Braveheart Bio 筹备 3 亿美元 IPO 计划 (待定股票代码：$BRVE)
· seekingalpha.com
Braveheart Bio 拟通过 $BRVE IPO 募资 3 亿美元，旨在继 2 期临床试验取得强劲结果后，推进治疗肥厚型心肌病（HCM）的候选药物 BHB-1893。
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...